GlaxoSmithKline is currently experiencing a shortage of Horizant 600mg extended-release tablets, according to the FDA. Horizant is a prodrug of gabapentin that is indicated for postherpetic neuralgia and for moderate-to-severe primary restless legs syndrome in adults.
In patients with restless legs syndrome, dopamine agonists and calcium channel alpha-2-delta ligands are effective in reducing symptoms and improving sleep and quality of life, although adverse events are common and often lead to treatment withdrawals.
As the U.S. population ages, clinicians can expect more geriatric patients seeking evaluation and treatment for sleep disorders.
The FDA notified healthcare professionals about a possible increased risk of heart failure with Mirapex (pramipexole tablets; Boehringer Ingelheim).
UCB announced that Neupro (rotigotine transdermal system) is now available as a once-daily patch for the treatment of signs and symptoms of early and advanced stage idiopathic Parkinson’s disease (PD) and moderate-to-severe primary restless legs syndrome (RLS).
UCB announced that the FDA has approved Neupro (rotigotine transdermal system) for the treatment of the signs and symptoms of advanced stage idiopathic Parkinson’s disease (PD) and as a treatment for moderate-to-severe primary restless legs syndrome (RLS).
Pfizer announced results from its Phase 3 study of Lyrica (pregabalin) for the treatment of restless leg syndrome (RLS).
GlaxoSmithKline and XenoPort announced that the FDA has approved Horizant (gabapentin enacarbil extended-release tablets) for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS) in adults.
